Drug and Alcohol Review
December 1, 2004
BOB Green, David J. Kavanagh, Ross McD. Young
Abstract: Psychoses are relatively low prevalence disorders that have a disproportionately negative impact on individuals and society. Cannabis use is one factor that can exacerbate the negative consequences associated with psychotic disorders. Relatively few studies have examined the effects or reasons for using cannabis self‐reported by individuals with psychosis. The present study is the...
Drug and Alcohol Review
November 30, 2004
Wayne Hall, Louisa Degenhardt, Maree Teesson
105 citations
This paper evaluates three hypotheses about the relationship between cannabis use and psychosis in the light of recent evidence from prospective epidemiological studies. These are that: (1) cannabis use causes a psychotic disorder that would not have occurred in the absence of cannabis use; (2) that cannabis use may precipitate schizophrenia or exacerbate its symptoms; and (3) that cannabis use...
Neuroimage
November 2004
Dana A Eldreth, John A Matochik, Jean L Cadet et al.
We used PET (15)O and a modified version of the Stroop task to determine if 25-day abstinent heavy marijuana (MJ) users have persistent deficits in executive cognitive functioning (ECF) and brain activity. Performance on a modified version of the Stroop task and brain activity was compared between 25-day abstinent, heavy marijuana users (n = 11), and a matched comparison group (n = 11). The...
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice
October 1, 2004
Dieter Caspari, Thomas Wobrock
6 citations
Ziel: Der vorliegende Beitrag gibt einen Überblick über die Entwicklung von Konzepten zu psychotischen Störungen bei Cannabiskonsumenten und diskutiert insbesondere die Zusammenhänge zwischen Cannabiskonsum und schizophrenen Störungen. Methode: Ein Rückblick über relevante Arbeiten zur Thematik zeigt, dass die psychiatrische und psychopathologische Beschäftigung mit Cannabis und seinen...
European Journal of Neuroscience
October 2004
Guadalupe Soria, Anna Castañé, Fernando Berrendero et al.
A2A adenosine and CB1 cannabinoid receptors are highly expressed in the central nervous system, where they modulate numerous physiological processes including adaptive responses to drugs of abuse. Both purinergic and cannabinoid systems interact with dopamine neurotransmission (through A2A and CB1 receptors, respectively). Changes in dopamine neurotransmission play an important role in...
Addiction
October 1, 2004
N. C. Stefanis, Philippe Delespaul, Cécile Henquet et al.
ABSTRACTAims To investigate the effect of exposure to cannabis early in adolescence on subclinical positive and negative symptoms of psychosis.Design Cross‐sectional survey in the context of an ongoing cohort study.Setting Government‐supported general population cohort study.Participants A total of 3500 representative 19‐year olds in Greece.Measurements Subjects filled in the 40‐item Community...
Toxicon
September 15, 2004
E A Carlini
This review analyses the therapeutic usefulness of Delta(9)-tetrahydrocannabinol and its potential to induce adverse reactions on humans. During the last 30 years an enormous amount of research was carried out resulting in the disclosure of the cannabinoid system in Central Nervous System, with its CB(1) and CB(2) receptors, and the agonist anandamide. Under the clinical point of view,...
Addiction
September 15, 2004
David M. Fergusson
6 citations
The report by Stefanis et al. (2004) adds to the evidence linking the heavy use of cannabis with increased risks of psychosis or psychotic symptoms. The advantages of this study include: a large and representative sample; measurement of multiple dimensions of psychotic symptoms; statistical control for reverse causality mediated via distress; and adjustment for comorbid depression. The study...
Addiction
September 15, 2004
Stanley Zammit, Glyn Lewis
20 citations
Evidence for an association between cannabis use and psychosis continues to accumulate. A number of population-based longitudinal studies have found that cannabis use is associated with the later development of psychotic symptoms or psychotic diagnoses [1–6]. Studies of subjects with schizophrenia show associations between cannabis use and increased levels of positive symptoms [7,8] as well as...
British Journal of Pharmacology
September 2004
Carl R. Lupica, Arthur C Riegel, Alexander F. Hoffman
The reward circuitry of the brain consists of neurons that synaptically connect a wide variety of nuclei. Of these brain regions, the ventral tegmental area (VTA) and the nucleus accumbens (NAc) play central roles in the processing of rewarding environmental stimuli and in drug addiction. The psychoactive properties of marijuana are mediated by the active constituent, Delta(9)-THC, interacting...
Experimental and Clinical Psychopharmacology
August 2004
Jenny L Wiley, Kari L LaVecchia, Natalie E Karp et al.
Efforts to determine whether Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and anandamide elicit similar discriminative stimulus effects have yielded conflicting results. The difficulty in establishing a discriminative cue to anandamide may be due to its metabolic instability. Rats were trained to discriminate either Delta(9)-THC or O-1812, a metabolically stable anandamide analog, from vehicle...
Progress in neuro-psychopharmacology & biological psychiatry
August 2004
Harold Kalant
Recent research has clarified a number of important questions concerning adverse effects of cannabis on health. A causal role of acute cannabis intoxication in motor vehicle and other accidents has now been shown by the presence of measurable levels of Delta(9)-tetrahydrocannabinol (THC) in the blood of injured drivers in the absence of alcohol or other drugs, by surveys of driving under the...
Neuropsychopharmacology
August 2004
Deepak Cyril D'Souza, Edward Perry, Lisa Macdougall et al.
Recent advances in the understanding of brain cannabinoid receptor function have renewed interest in the association between cannabinoid compounds and psychosis. In a 3-day, double-blind, randomized, and counterbalanced study, the behavioral, cognitive, and endocrine effects of 0, 2.5, and 5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 22 healthy individuals,...
Behavioural Pharmacology
July 2004
Scott D Lane, Don R Cherek, C J Pietras et al.
Acute marijuana administration may alter response-reinforcer relationships via a change in reinforcer efficacy, but may also impair coordination and motor function. One approach to evaluating drug effects on both motor function and reinforcer efficacy involves fitting the matching law equation to data obtained under multiple variable interval (VI) schedules. The present report describes an...
Praxis
June 2, 2004
Michael P Schaub, Wulf Rössler, Rudolf Stohler
The present review focuses on articles dealing with clinical or epidemiological studies on the association between cannabis use and psychoses. Included are all articles published since 1990 that were located by a Medline or Psyclit data-base research and those earlier articles that are needed for a correct understanding of studies published during the index episode. The three main topics found...
Epidemiologia e Psichiatria Sociale
June 1, 2004
Helene Verdoux, Marie Tournier
SummaryObjective – The nature of the link between cannabis use and psychosis remains to be clarified. Method – The paper reviews the evidence suggesting that cannabis may be a risk factor for psychosis onset. Results – Cross-sectional and retro- spective epidemiological studies show that individuals with psychosis use cannabis more often than other individuals in the gener- al population. It...
Drugs Education Prevention and Policy
June 1, 2004
Sarah Riley, Emma Hayward
52 citations
A survey of drug use in the past year was completed by 124 clubbers (50% male, 50% female, age range 14–44, mean 24 years). Participants were self selecting and recruited in clubs and pre-club bars. Prevalence rates for alcohol, cannabis, and ecstasy were over 80%; 63% reported cocaine and 53% amphetamine use, 15%–43% used ketamine, psilocybin, LSD and nitrites. A pattern of polydrug and...
Cambridge University Press eBooks
May 27, 2004
Don H. Linszen, Bart D. Peters, Lieuwe de Haan
9 citations
As detailed elsewhere in this book (Chapter 3), cannabis has been used for centuries to produce euphoria and relaxation as desired mental effects. However, adverse effects of intoxication with cannabis include anxiety and panic (Thomas, 1996; Reilly et al. , 1998), depression (Bovasso, 2001; Patton et al. , 2002: see Chapter 4), and impairment in certain domains of cognitive function (see...
Cambridge University Press eBooks
May 27, 2004
Wayne Hall, Louisa Degenhardt
27 citations
There are good reasons to be concerned about the possibility that cannabis use may be a cause of psychotic disorders. Psychoses are serious and disabling disorders (Bromet et al. , 1995). Cannabis is widely used during late adolescence in many developed societies (Hall et al. , 1999), and high doses of tetrahydrocannabinol (THC) – the psychoactive substance in cannabis – have been reported to...
Neuropsychopharmacology
May 2004
Boris B. Quednow, Kai‐uwe Kühn, Klaus Hoenig et al.
Chronic administration of 3,4-methylenedioxymethamphetamine (MDMA) is associated with long-term depletion of serotonin (5-HT) and loss of 5-HT axons in the brains of rodents and nonhuman primates. Despite the broad database concerning the selective serotonergic neurotoxicity of recreational MDMA consumption by humans, controversy still exists with respect to the question of whether the...